Kiniksa [KNSA] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

Kiniksa Pharmaceuticals, Ltd.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Kiniksa Pharmaceuticals, Ltd. wins in 8 metrics, Haleon Plc - ADR wins in 12 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Kiniksa Pharmaceuticals, Ltd. Haleon Plc - ADR Better
P/E Ratio (TTM) 57.39 18.72 Haleon Plc - ADR
Price-to-Book Ratio 5.78 1.88 Haleon Plc - ADR
Debt-to-Equity Ratio 1.67 52.37 Kiniksa Pharmaceuticals, Ltd.
PEG Ratio -0.22 15.42 Haleon Plc - ADR
EV/EBITDA 36.68 33.08 Haleon Plc - ADR
Profit Margin (TTM) 8.71% 15.11% Haleon Plc - ADR
Operating Margin (TTM) 9.78% 23.17% Haleon Plc - ADR
EBITDA Margin (TTM) 9.78% 23.17% Haleon Plc - ADR
Return on Equity 11.73% 10.27% Kiniksa Pharmaceuticals, Ltd.
Return on Assets (TTM) 7.18% 4.67% Kiniksa Pharmaceuticals, Ltd.
Free Cash Flow (TTM) $136.42M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return 76.83% -20.18% Kiniksa Pharmaceuticals, Ltd.
Price-to-Sales Ratio (TTM) 4.86 3.78 Haleon Plc - ADR
Enterprise Value $2.89B $122.54B Haleon Plc - ADR
EV/Revenue Ratio 4.27 8.23 Kiniksa Pharmaceuticals, Ltd.
Gross Profit Margin (TTM) 54.99% 55.38% Haleon Plc - ADR
Revenue per Share (TTM) $9 $2 Kiniksa Pharmaceuticals, Ltd.
Earnings per Share (Diluted) $0.75 $0.50 Kiniksa Pharmaceuticals, Ltd.
Beta (Stock Volatility) 0.06 0.33 Kiniksa Pharmaceuticals, Ltd.
Short % of Float 9.62% 0.43% Haleon Plc - ADR

Kiniksa Pharmaceuticals, Ltd. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

KNSA
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Kiniksa Pharmaceuticals, Ltd.-3.10%-11.22%-18.55%2.02%17.12%11.71%
Haleon Plc - ADR-1.58%-5.84%-5.84%-19.96%-10.03%-13.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Kiniksa Pharmaceuticals, Ltd.76.83%231.14%262.67%149.25%149.25%149.25%
Haleon Plc - ADR-20.18%9.16%22.27%22.27%22.27%22.27%

Performance & Financial Health Analysis: Kiniksa Pharmaceuticals, Ltd. vs Haleon Plc - ADR

MetricKNSAHLN
Market Information
Market Cap i$3.29B$42.40B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i755,8516,594,249
90 Day Avg. Volume i660,0377,985,230
Last Close$46.93$8.70
52 Week Range$26.27 - $59.87$8.69 - $11.42
% from 52W High-21.61%-23.82%
All-Time High$59.87 (May 12, 2026)$11.42 (Jun 02, 2025)
% from All-Time High-21.61%-23.82%
Growth Metrics
Quarterly Revenue Growth0.65%0.01%
Quarterly Earnings Growth0.65%0.86%
Financial Health
Profit Margin (TTM) i0.09%0.15%
Operating Margin (TTM) i0.10%0.23%
Return on Equity (TTM) i0.12%0.10%
Debt to Equity (MRQ) i1.6752.37
Cash & Liquidity
Book Value per Share (MRQ)$7.44$4.99
Cash per Share (MRQ)$5.41$0.15
Operating Cash Flow (TTM) i$137.98M$3.56B
Levered Free Cash Flow (TTM) i$97.89M$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: Kiniksa Pharmaceuticals, Ltd. vs Haleon Plc - ADR

MetricKNSA (Apr 24, 2026)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i57.3918.72
Forward P/E i29.1515.42
PEG Ratio i-0.2215.42
Price to Sales (TTM) i4.863.78
Price to Book (MRQ) i5.781.88
Market Capitalization
Market Capitalization i$3.29B$42.40B
Enterprise Value i$2.89B$122.54B
Enterprise Value Metrics
Enterprise to Revenue i4.278.23
Enterprise to EBITDA i36.6833.08
Risk & Other Metrics
Beta i0.060.33
Book Value per Share (MRQ) i$7.44$4.99

Financial Statements Comparison: Kiniksa Pharmaceuticals, Ltd. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricKNSA (2025)HLN (2025)
Revenue/Sales i677.56M11.03B
Cost of Goods Sold i307.22M3.95B
COGS % of Revenue i45.3%35.8%
Gross Profit i370.35M7.08B
Gross Margin i54.7%64.2%
Research & Development i96.85M316.00M
Operating Income (EBIT) i77.22M2.41B
Operating Margin i11.4%21.9%
EBITDA i78.78M2.81B
EBITDA Margin i11.6%25.5%
Pre-Tax Income i88.87M2.15B
Pre-Tax Income % of Revenue i13.1%19.5%
Income Tax i29.86M472.00M
Income Tax % of Revenue i4.4%4.3%
Net Income (Profit) i59.01M1.68B
Profit Margin i8.7%15.2%

Balance Sheet & Liquidity Metrics

MetricKNSA (2025)HLN (2025)
Cash & Equivalents i165.60M1.26B
Total Current Assets i527.18M4.55B
Total Current Assets % of Revenue i77.8%41.3%
Total Current Liabilities i139.18M4.93B
Total Current Liabilities % of Revenue i20.5%44.7%
Long-Term Debt i6.51M7.75B
Long-Term Debt % of Revenue i1.0%70.2%
Total Shareholders Equity i567.61M16.48B
Retained Earnings i-462.14M27.85B
Retained Earnings % of Revenue i-68.2%252.5%
Property, Plant & Equipment i13.81M1.00M

Cash Flow Statement Comparison

MetricKNSA (2025)HLN (2025)
Operating Cash Flow i124.01M2.19B
Operating Cash Flow % of Revenue i18.3%19.8%
Capital Expenditures i-1.57M-322.00M
Free Cash Flow i136.42M2.22B
FCF Margin i20.1%20.1%
Debt Repayment iN/A-1.35B
Common Stock Repurchase i-7.73M-654.00M

Short Interest & Institutional Ownership Analysis

MetricKNSAHLN
Shares Short i4.09M19.28M
Short Ratio i6.092.14
Short % of Float i9.62%0.43%
Shares Outstanding i76.29M8.91B
Float Shares i39.90M8.86B
% Held by Insiders i3.58%0.01%
% Held by Institutions i103.89%12.74%
% Held by Public i-7.47%87.25%

Dividend Analysis & Yield Comparison: Kiniksa Pharmaceuticals, Ltd. vs Haleon Plc - ADR

MetricKNSAHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025